The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Baseline demographics of neuroendocrine tumor patients presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database.
Carrie C. Zornosa
No relevant relationships to disclose
Michael A. Choti
Honoraria - NCCN
Sarah Bobiak
No relevant relationships to disclose
Matthew Kulke
Consultant or Advisory Role - Ipsen; Lexicon; Molecular Insight Pharmaceuticals; Novartis; Pfizer
Research Funding - Novartis
James C. Yao
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Emily K. Bergsland
Consultant or Advisory Role - Novartis (U); Pfizer (U)
Research Funding - Genentech; NCCN; Novartis; OSI Pharmaceuticals
Eric K. Nakakura
Research Funding - Lexicon; NIH
Mark Bloomston
No relevant relationships to disclose
Al B. Benson
Employment or Leadership Position - NCCN (U)
Research Funding - NCCN
Manisha H. Shah
Research Funding - ImClone Systems; Novartis
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Genentech
Research Funding - Amgen; Novartis; Pfizer